![Brian Burkavage](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 35 $ al 31/05/2026
Brian Burkavage is Chief Financial & Accounting Officer at Damora Therapeutics, Inc. starting in 2026.
Former positions include Chief Accounting Officer at IO Biotech, Inc. from 2022 to 2025, Controller at Passage Bio, Inc. from 2020 to 2021, and Director-Financial Planning & Analysis at Aclaris Therapeutics, Inc. from 2017 to 2020.
Education includes undergraduate and graduate degrees from the University of Notre Dame.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
IO BIOTECH, INC. 0,02 % | 02/04/2025 | 11.500 ( 0,02 % ) | 35 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| DAMORA THERAPEUTICS, INC. | Director Financiero/CFO | 01/05/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
| IO BIOTECH, INC. | Comptroller/Controller/Auditor | 12/12/2025 |
| PASSAGE BIO, INC. | Comptroller/Controller/Auditor | 01/01/2021 |
| ACLARIS THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2020 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
University of Notre Dame
 University of Notre Dame Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aclaris Therapeutics, Inc.
 Aclaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel drug candidates for immuno-inflammatory diseases | Health Technology |
Passage Bio, Inc.
 Passage Bio, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of monogenic central nervous system disorders | Health Technology |
Galecto, Inc.
 Galecto, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of severe diseases | Health Technology |
IO Biotech, Inc.
 IO Biotech, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel, immune-modulating cancer therapies | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
